mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company

The coronavirus disease 2019 (COVID-19) pandemic has been the defining public health emergency of our time. In Switzerland, messenger RNA (mRNA) vaccines were and still are widely utilized as a critical component of the Federal Office of Public Health (FOPH)’s preventative mitigation strategy. The d...

Descripción completa

Detalles Bibliográficos
Autores principales: Killeen, Tim, Kermer, Vanessa, Troxler Saxer, Rahel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683226/
https://www.ncbi.nlm.nih.gov/pubmed/38012751
http://dx.doi.org/10.1186/s40545-023-00652-y
_version_ 1785151147367989248
author Killeen, Tim
Kermer, Vanessa
Troxler Saxer, Rahel
author_facet Killeen, Tim
Kermer, Vanessa
Troxler Saxer, Rahel
author_sort Killeen, Tim
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic has been the defining public health emergency of our time. In Switzerland, messenger RNA (mRNA) vaccines were and still are widely utilized as a critical component of the Federal Office of Public Health (FOPH)’s preventative mitigation strategy. The development, conditional approval and worldwide roll-out of mRNA vaccines against COVID-19 proceeded at an unprecedented pace and presented myriad challenges for manufacturers. In this review, we discuss, from the perspective of the Swiss affiliate of a global biopharmaceutical company, the clinical, regulatory, pharmacovigilance and logistical considerations of making a mRNA COVID-19 vaccine available to the Swiss population during a pandemic as rapidly as possible while ensuring strict adherence to safety and quality standards.
format Online
Article
Text
id pubmed-10683226
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106832262023-11-30 mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company Killeen, Tim Kermer, Vanessa Troxler Saxer, Rahel J Pharm Policy Pract Review The coronavirus disease 2019 (COVID-19) pandemic has been the defining public health emergency of our time. In Switzerland, messenger RNA (mRNA) vaccines were and still are widely utilized as a critical component of the Federal Office of Public Health (FOPH)’s preventative mitigation strategy. The development, conditional approval and worldwide roll-out of mRNA vaccines against COVID-19 proceeded at an unprecedented pace and presented myriad challenges for manufacturers. In this review, we discuss, from the perspective of the Swiss affiliate of a global biopharmaceutical company, the clinical, regulatory, pharmacovigilance and logistical considerations of making a mRNA COVID-19 vaccine available to the Swiss population during a pandemic as rapidly as possible while ensuring strict adherence to safety and quality standards. BioMed Central 2023-11-27 /pmc/articles/PMC10683226/ /pubmed/38012751 http://dx.doi.org/10.1186/s40545-023-00652-y Text en © Pfizer Inc. 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Killeen, Tim
Kermer, Vanessa
Troxler Saxer, Rahel
mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
title mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
title_full mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
title_fullStr mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
title_full_unstemmed mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
title_short mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
title_sort mrna vaccine development during the covid-19 pandemic: a retrospective review from the perspective of the swiss affiliate of a global biopharmaceutical company
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683226/
https://www.ncbi.nlm.nih.gov/pubmed/38012751
http://dx.doi.org/10.1186/s40545-023-00652-y
work_keys_str_mv AT killeentim mrnavaccinedevelopmentduringthecovid19pandemicaretrospectivereviewfromtheperspectiveoftheswissaffiliateofaglobalbiopharmaceuticalcompany
AT kermervanessa mrnavaccinedevelopmentduringthecovid19pandemicaretrospectivereviewfromtheperspectiveoftheswissaffiliateofaglobalbiopharmaceuticalcompany
AT troxlersaxerrahel mrnavaccinedevelopmentduringthecovid19pandemicaretrospectivereviewfromtheperspectiveoftheswissaffiliateofaglobalbiopharmaceuticalcompany

Ejemplares similares